Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

Alida C. weidenaar, Ajra ter Elst, PhD, Gineke Koopmans-Klein, Stefano Rosati, MD, Wilfred F.A. den Dunnen, MD, PhD, Tiny G.J. Meeuwsen-de Boer, Willem A. Kamps, MD, PhD, Edo Vellenga, MD, PhD, Evelina S.J.M. de Bont, MD, PhD

Blood (2010) 116 (21): 2712.

https://doi.org/10.1182/blood.V116.21.2712.2712

Published: 2010

Journal Articles

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.

Hendrik JM de Jonge, Peter Valk, PhD, Kim R Kampen, Arja ter Elst, PhD, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD, C. Michel Zwaan, MD, PhD, Marry M van den Heuvel-Eibrink, MD, PhD, Willem A. Kamps, MD, PhD, Ruud Delwel, PhD, Bob Lowenberg, MD, PhD, Eveline S de Bont, MD, PhD

Blood (2009) 114 (22): 997.

https://doi.org/10.1182/blood.V114.22.997.997

Published: 2009

Journal Articles

AML1/RUNX1, One of the Most Common Targets of Aberration in Acute Myeloid Leukemia as a Transcriptional Regulator of Vascular Endothelial Growth Factor (VEGFA).

Arja ter Elst, PhD, Bin Ma, Frank Scherpen, Bart-Jan A.T. Wierenga, Jan Jacob Schuringa, PhD, Jenny Douwes, Willem A. Kamps, MD/PhD, Evelina S. de Bont, MD/PhD

Blood (2007) 110 (11): 1618.

https://doi.org/10.1182/blood.V110.11.1618.1618

Published: 2007

Journal Articles

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

Alida C. Weidenaar, Hendrik J.M. de Jonge, Vaclav Fidler, PhD, Arja ter Elst, PhD, Tiny Meeuwsen, Jenny Douwes, Jessica C.A. Bouma, PhD, Karel Hählen, MD/PhD, Willem A. Kamps, MD/PhD, Evelina S. de Bont, MD/PhD

Blood (2007) 110 (11): 4199.

https://doi.org/10.1182/blood.V110.11.4199.4199

Published: 2007

Journal Articles

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Hendrik J.M. de Jonge, Arja ter Elst, PhD, H. Marike Boezen, PhD, Alida C. Weidenaar, Frank J.G. Scherpen, Jessica C.A. Bouma-ter Steege, PhD, Gertjan J.L. Kaspers, MD/PhD, Bianca F. Goemans, MD, Ursula Creutzig, MD/PhD, Willem A. Kamps, MD/PhD, Evelina S.J.M. de Bont, MD/PhD

Blood (2006) 108 (11): 838.

https://doi.org/10.1182/blood.V108.11.838.838

Published: 2006

NARROW

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.

AML1/RUNX1, One of the Most Common Targets of Aberration in Acute Myeloid Leukemia as a Transcriptional Regulator of Vascular Endothelial Growth Factor (VEGFA).

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Email alerts

ASH Publications

American Society of Hematology

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.

AML1/RUNX1, One of the Most Common Targets of Aberration in Acute Myeloid Leukemia as a Transcriptional Regulator of Vascular Endothelial Growth Factor (VEGFA).

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only